Floatz logo

Irinotecan

Locally Advanced

Salah Azaïz Cancer InstituteSmall moleculePhase 3Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Locally Advanced cohort.

Asset / SponsorPhaseRating
Bms-907351
Centre Francois Baclesse
Phase 4BB
(+)-VINCRISTINE
Amgen
Phase 3BB
Nivolumab
Centre Francois Baclesse
Phase 4B
Epirubicin
PMV Pharmaceuticals, Inc
Phase 2B
Conatumumab
Amgen
Phase 2B

View all 26 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →